The main emphasis of his lab's current research is to understand molecular tumor heterogeneity as a cause of drug resistance, utilizing genome-wide approaches in modeling disease causality stratifying patients for advancing diagnostic and prognostic markers and therapy. He has published more than 50 seminal papers and book chapters, received several prestigious merit awards in cancer research, most recently from the Danish Cancer Society, 2015. His laboratory has received many competitive investigator awards/grants from the Novo Nordisk Foundation (Hallas-Møller), AP Møller Foundation, Lundbeck Foundation, Danish Cancer Society (Break Cancer), Medical Research Council for elite science in Denmark, and several Marie Sklodowska-Curie European Postdoc fellowships.